

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/596,740	Applicant: Clifford David Jones <i>et al</i>
371 Filing Date: Not yet known	Attorney Docket No.: 101346-1P US
Examiner: Not yet known	Group Art Unit: 3749
Customer No.: 44992	Confirmation No.: 1005
Title: PYRIMIDINES WITH TIE2 (TEK) ACTIVITY	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Notification to Comply with Requirements for Patent Applications Containing Nucleotide  
and/or Amino Acid Sequence Disclosures**

Sir:

Responsive to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures, dated April 2, 2007, Applicant believes no Sequence Listing is required. Applicant did contact Barbara Campbell who sent the Notice to comply and discussed with her the absence of any sequences in the application. She advised Applicants to send a facsimile to her stating the absence of any sequences, which applicants have done.

Respectfully submitted,

/Carol A. Loeschorn/

---

Name: Carol A. Loeschorn  
Dated: June 1, 2007  
Reg. No.: 35590  
Phone No.: 781 839 4002

Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham,  
MA 02451

CCPF




## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/596,740	FIRST NAMED APPLICANT Clifford David Jones	ATTY. DOCKET NO. 101346-1P US
INTERNATIONAL APPLICATION NO. PCT/GB04/05332		
I.A. FILING DATE 12/20/2004		PRIORITY DATE 12/24/2003

44992  
 ASTRAZENECA R&D BOSTON  
 35 GATEHOUSE DRIVE  
 WALTHAM, MA 02451-1215



CONFIRMATION NO. 1005  
 371 FORMALITIES LETTER



\*OC000000023157444\*

Date Mailed: 04/02/2007

### NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/596,740	PCT/GB04/05332	101346-1P US